DSIP side effects reported in human research include immediate sleep pressure, headache, nausea, vertigo and sweating. Two people in a 107-person withdrawal study developed hypotension, and another had repeated brief episodes of discomfort with sweating and nausea. The larger concern is uncertainty: the studies were small, mostly used intravenous DSIP and lasted no longer than 15 days. They cannot establish the safety of long-term or subcutaneous use.
For the compound’s background and proposed sleep role, see what DSIP is. Here, the question is narrower: what has actually been observed, and what remains unmeasured?
DSIP side effects at a glance
The published record does not support a reliable percentage for most effects. FDA’s 2026 evidence review found 209 people who had received intravenous emideltide, the regulatory name used for DSIP, across studies lasting 1 to 15 days. It found no human clinical safety data for the proposed subcutaneous route.
| Reported effect | What the human evidence shows | How to read it |
|---|---|---|
| Sleep pressure or drowsiness | Five of six healthy volunteers felt immediate pressure to sleep in a 1981 crossover study | Expected from the intended sleep effect, but still relevant to driving or other alertness-dependent tasks |
| Headache, nausea, vertigo or sweating | Nine of 107 withdrawal-study participants had minor, transient symptoms | The study population was already in withdrawal, so cause is difficult to separate |
| Low blood pressure | Two of 107 participants developed hypotension; one had progressive hypotension after another infusion | A real signal in a weak study, not a known incidence rate for current products |
| Injection-site redness, soreness or swelling | No human subcutaneous trial quantified these reactions | A possible local injection effect with an unknown DSIP-specific rate |
| Vivid dreams | Reported anecdotally, not as a measured adverse-event rate in the clinical studies | A personal report, not an established frequency |
The distinction between “reported” and “common” matters. A handful of reports cannot show how often an event occurs, and an absence of reports in a tiny study cannot show that an event is rare.
What the human studies actually reported
In the first controlled human study, six healthy adults received DSIP by slow intravenous infusion. Five described an immediate pressure to sleep. Two hours later, investigators did not find reduced vigilance or impaired mental function, and the paper reported no psychological, physiological or biochemical adverse effects (Schneider-Helmert et al., 1981). That is reassuring for six short exposures, not proof of broad safety.
Kaeser’s 1984 study gave a series of 10 injections to seven people with severe insomnia. It was open-label and had no placebo group (Kaeser, European Neurology 1984). A later double-blind study enrolled 16 people with chronic insomnia and used three intravenous administrations; the measured sleep effects were weak and the authors found little therapeutic value (Bes et al., Neuropsychobiology 1992). Together, these studies show why decades of publication do not equal a modern safety dataset: the individual trials remained tiny and brief.
The clearest adverse-event details came from 107 inpatients undergoing alcohol or opioid withdrawal. Nine had transient sweating, headache, nausea or vertigo. Two developed hypotension, while a third had repeated 15-minute episodes of discomfort, sweating and nausea. The trial lacked a control group, and withdrawal itself can cause several of the same symptoms. The authors described tolerance as generally good aside from headaches in a few patients (Dick et al., European Neurology 1984).
What short studies cannot tell us
There is no adequate long-term human dataset for DSIP. The studies do not establish rates for rare allergic reactions, persistent blood-pressure effects, interactions, reproductive risks or risks from months of intermittent exposure. They also do not settle whether the free-base and acetate forms behave identically in a finished preparation.
Route is another gap. Historical participants generally received intravenous infusions in monitored settings. Contemporary compounded products may be used subcutaneously, but FDA found no clinical safety study for that route. Local redness or soreness is possible with an injection, yet no defensible DSIP-specific percentage exists. Reports of unusually vivid dreams sit in the same category: worth discussing if they are disruptive, but anecdotal rather than a demonstrated trial rate.
FDA also identified a potential immune-response concern from peptide aggregation and impurities. That is a formulation risk, not evidence that a known percentage of DSIP users develops an immune reaction. It is one reason a pharmacy-dispensed product and a grey-market vial are not interchangeable.
The July 2026 FDA review, in context
DSIP is not FDA-approved. On July 24, 2026, the Pharmacy Compounding Advisory Committee considered emideltide free base and emideltide acetate for the 503A Bulks List. The official meeting broadcast recorded the same 6 yes, 7 no and 1 abstention tally for each form, so the committee did not recommend either one for inclusion.
As of August 2026, that vote was advisory and rulemaking remained pending. FDA explains that advisory recommendations are nonbinding and that bulks-list decisions proceed through notice-and-comment rulemaking on its 503A compounding page. The vote was not a finding that one reported symptom proved DSIP unsafe. It reflected the full evidence record, including limited characterization, no subcutaneous human safety data and uncertain long-term risk.
FDA review status is one input, not a marketing gate: a licensed provider may still prescribe a compounded formulation when appropriate, and that decision is between the patient and prescriber.
How a provider weighs DSIP risks
A useful review starts with the reason for poor sleep, because sleep apnea, restless legs, mood disorders, substance withdrawal and medication effects call for different care. It also covers current medicines and alcohol use. Formal DSIP interaction studies are lacking, so sedating drugs and blood-pressure-lowering medicines deserve particular attention rather than assumptions about compatibility.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The route, amount and timing are set by that prescriber; DSIP dosing considerations are a separate discussion from tolerability.
Prompt clinical advice is warranted for fainting, near-fainting, severe or persistent dizziness, or an injection-site reaction that is spreading or accompanied by fever. Trouble breathing, facial or tongue swelling, or rapidly spreading hives require emergency care. A milder symptom still belongs in follow-up if it persists, worsens or interferes with daytime function.
The practical way to read the risk
The historic trials did not reveal a large pattern of severe toxicity. They also were not capable of ruling one out. The most accurate summary is that short-term intravenous DSIP was often tolerated in small studies, while headache, nausea, vertigo, sweating, hypotension and immediate sleep pressure were reported. Subcutaneous and long-term safety remain unquantified.
For a broader look at sleep and stress-support options, the calming and stress relief hub keeps the goals separate from the evidence for any one compound.